Transforming women's health

The first non hormonal treatment for women suffering from genitourinary syndrome of menopause.

Genitourinary Syndrome
of Menopause

GSM, also known as vaginal atrophy, is a thinning and inflammation of the vaginal walls that is a consequence of reduced estrogen production. This condition can make it painful just to sit, walk or urinate.

Image
The Revolutionary Device for treating Vaginal Atrophy

The Revolutionary Device for treating GSM

A treatment that fits in with your daily life. The accessible, safe, and affordable treatment that is suitable for everyone – creating a stronger you.

Image

Patient Impact

GSM impacts a large number of people around the world, here’s what the research is telling us about our patients.

Milestones Completed to Date

Q3 2020

Intellectual Property (IP) Filed

Q3 2020

Q2 2022

US Institutional Review Board Study Completed

Q2 2023

Functional Prototype Designed

Q2 2023

Q2 2023

Start of First-in-Human Trial

Q2 2024

Identification of Clinical Trial Sites in Europe & US

Q2 2024

Q3 2024

De-risk of Manufacturability and Scaling

Q3 2024

FDA Investigational Device Exemption Granted for Pilot Trial

Q3 2024

Q4 2024

Completion of First-in-Human Trial

Q2 2025

Start of Pilot Trial

Q2 2025

Disclaimer: This product is currently under development and has not been approved for sale by the U.S. Food and Drug Administration (FDA) or under the EU Medical Device Regulation (MDR). It is not available for purchase in the United States or the European Union.